A phase II study of 99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.
Kevin Mark Slawin
Research Funding - Molecular Insight Pharmaceuticals
William J. Ellis
Research Funding - Progenics Pharmaceuticals
Peter Tenke
Research Funding - Progenics Pharmaceuticals
Steven Joniau
Research Funding - Progenics Pharmaceuticals
Boris Y. Alekseev
Research Funding - Progenics Pharmaceuticals
Istvan Buzogány
Research Funding - Progenics Pharmaceuticals
Sergey Mishugin
Research Funding - Progenics Pharmaceuticals
Eric A. Klein
Research Funding - Progenics Pharmaceuticals
R. Jeffrey Karnes
Research Funding - Progenics Pharmaceuticals
Douglas Scherr
Research Funding - Progenics Pharmaceuticals
Bertram E. Yuh
Research Funding - Progenics Pharmaceuticals
David Frasier Jarrard
Research Funding - Progenics Pharmaceuticals
Edouard John Trabulsi
Research Funding - Progenics Pharmaceuticals
Josef Stolz
Research Funding - Progenics Pharmaceuticals
John Babich
No relevant relationships to disclose
Hagop Youssoufian
Employment or Leadership Position - Progenics Pharmaceuticals
Nancy Stambler
Employment or Leadership Position - Progenics Pharmaceuticals
Thomas Armor
Employment or Leadership Position - Progenics Pharmaceuticals
Robert Joseph Israel
Employment or Leadership Position - Progenics Pharmaceuticals
Stock Ownership - Progenics Pharmaceuticals